دورية أكاديمية
أعرض في EDS

High-Resolution Mass Spectrometry for the Measurement of PTH and PTH Fragments: Insights into PTH Physiology and Bioactivity.

التفاصيل البيبلوغرافية
العنوان: High-Resolution Mass Spectrometry for the Measurement of PTH and PTH Fragments: Insights into PTH Physiology and Bioactivity.
المؤلفون: Ulmer CZ; Clinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Kritmetapak K; Division of Nephrology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand., Singh RJ; Immunochemical Core Laboratory, Mayo Clinic, Rochester, Minnesota.; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota., Vesper HW; Clinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia., Kumar R; Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota.
المصدر: Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2022 Aug; Vol. 33 (8), pp. 1448-1458. Date of Electronic Publication: 2022 Apr 08.
نوع المنشور: Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, on behalf of the American Society of Nephrology Country of Publication: United States NLM ID: 9013836 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-3450 (Electronic) Linking ISSN: 10466673 NLM ISO Abbreviation: J Am Soc Nephrol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2023- : Hagerstown, MD : Wolters Kluwer Health, on behalf of the American Society of Nephrology
Original Publication: Baltimore, MD : Williams & Wilkins, c1990-
مواضيع طبية MeSH: Chronic Kidney Disease-Mineral and Bone Disorder* , Renal Insufficiency, Chronic*, Bone and Bones ; Humans ; Mass Spectrometry ; Parathyroid Hormone ; Peptide Fragments
مستخلص: Full-length parathyroid hormone (PTH 1-84) is crucial for the regulation of calcium and phosphate homeostasis and bone remodeling. PTH 1-84 is metabolized into various PTH fragments, which are measured with varying levels of efficiency by PTH immunoassays. These PTH fragments, which increase in serum as CKD progresses, could potentially modulate the effects of PTH 1-84 and contribute to CKD-associated bone disorders. To obtain a true biologic representation of total PTH bioactivity, it is necessary to measure not only PTH 1-84 but also PTH fragments that are present in circulation. Traditional second-generation PTH immunoassays collectively measure PTH 1-84, PTH fragments, and post-translationally modified PTH 1-84, making it difficult to accurately predict the character of underlying renal osteodystrophy. This review highlights current advances in methods available for PTH measurement and the clinical relevance of PTH fragments in CKD. We emphasize the usefulness of mass spectrometry as a potential reference method for PTH measurement.
(Copyright © 2022 by the American Society of Nephrology.)
References: Kritmetapak K, Losbanos LA, Hines JM, O’Grady KL, Ulmer CZ, Vesper HW, et al.: Chemical characterization and quantification of circulating intact PTH and PTH fragments by high-resolution mass spectrometry in chronic renal failure. Clin Chem 67: 843–853, 2021.
Zhang CX, Weber BV, Thammavong J, Grover TA, Wells DS: Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem 78: 1636–1643, 2006.
Lopez MF, Rezai T, Sarracino DA, Prakash A, Krastins B, Athanas M, et al.: Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 56: 281–290, 2010.
Ketha H, Singh RJ: Quantitation of parathyroid hormone in serum or plasma by liquid chromatography-tandem mass spectrometry. Methods Mol Biol 1378: 211–217, 2016.
Evenepoel P, Bover J, Ureña Torres P: Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int 90: 1184–1190, 2016.
Divieti P, John MR, Jüppner H, Bringhurst FR: Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143: 171–176, 2002.
Kritmetapak K, Singh RJ, Craig TA, Hines JM, Kumar R: Short carboxyl terminal parathyroid hormone peptides modulate human parathyroid hormone signaling in mouse osteoblasts. Biochem Biophys Res Commun 572: 15–19, 2021.
Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D’Amour P: Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142: 1386–1392, 2001.
Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al.: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44: 805–809, 1998.
Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH: Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144: 1135–1138, 2003.
Habener JF, Amherdt M, Ravazzola M, Orci L: Parathyroid hormone biosynthesis. Correlation of conversion of biosynthetic precursors with intracellular protein migration as determined by electron microscope autoradiography. J Cell Biol 80: 715–731, 1979.
Schmitt CP, Schaefer F, Bruch A, Veldhuis JD, Schmidt-Gayk H, Stein G, et al.: Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium. J Clin Endocrinol Metab 81: 4236–4243, 1996.
Schmitt CP, Schaefer F, Huber D, Zahn I, Veldhuis JD, Ritz E, et al.: 1,25(OH)2-vitamin D3 reduces spontaneous and hypocalcemia-stimulated pulsatile component of parathyroid hormone secretion. J Am Soc Nephrol 9: 54–62, 1998.
Martin KJ, Hruska KA, Lewis J, Anderson C, Slatopolsky E: The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration. J Clin Invest 60: 808–814, 1977.
van Ballegooijen AJ, Rhee EP, Elmariah S, de Boer IH, Kestenbaum B: Renal clearance of mineral metabolism biomarkers. J Am Soc Nephrol 27: 392–397, 2016.
D’Amour P, Huet PM, Segre GV, Rosenblatt M: Characteristics of bovine parathyroid hormone extraction by dog liver in vivo. Am J Physiol 241: E208–E214, 1981.
Rouleau MF, Warshawsky H, Goltzman D: Parathyroid hormone binding in vivo to renal, hepatic, and skeletal tissues of the rat using a radioautographic approach. Endocrinology 118: 919–931, 1986.
Martin K, Hruska K, Greenwalt A, Klahr S, Slatopolsky E: Selective uptake of intact parathyroid hormone by the liver: Differences between hepatic and renal uptake. J Clin Invest 58: 781–788, 1976.
Bringhurst FR, Stern AM, Yotts M, Mizrahi N, Segre GV, Potts JT Jr: Peripheral metabolism of PTH: Fate of biologically active amino terminus in vivo. Am J Physiol 255: E886–E893, 1988.
Bringhurst FR, Stern AM, Yotts M, Mizrahi N, Segre GV, Potts JT Jr: Peripheral metabolism of [35S]parathyroid hormone in vivo: influence of alterations in calcium availability and parathyroid status. J Endocrinol 122: 237–245, 1989.
D’Amour P, Räkel A, Brossard JH, Rousseau L, Albert C, Cantor T: Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: utility of PTH fragments/PTH(1-84) ratios derived from three generations of PTH assays. J Clin Endocrinol Metab 91: 283–289, 2006.
MacGregor RR, Hamilton JW, Kent GN, Shofstall RE, Cohn DV: The degradation of proparathormone and parathormone by parathyroid and liver cathepsin B. J Biol Chem 254: 4428–4433, 1979.
Hashizume Y, Waguri S, Watanabe T, Kominami E, Uchiyama Y: Cysteine proteinases in rat parathyroid cells with special reference to their correlation with parathyroid hormone (PTH) in storage granules. J Histochem Cytochem 41: 273–282, 1993.
D’Amour P, Palardy J, Bahsali G, Mallette LE, DeLéan A, Lepage R: The modulation of circulating parathyroid hormone immunoheterogeneity in man by ionized calcium concentration. J Clin Endocrinol Metab 74: 525–532, 1992.
Gardella TJ, Jüppner H, Wilson AK, Keutmann HT, Abou-Samra AB, Segre GV, et al.: Determinants of [Arg2]PTH-(1-34) binding and signaling in the transmembrane region of the parathyroid hormone receptor. Endocrinology 135: 1186–1194, 1994.
Lee C, Gardella TJ, Abou-Samra AB, Nussbaum SR, Segre GV, Potts JT Jr, et al.: Role of the extracellular regions of the parathyroid hormone (PTH)/PTH-related peptide receptor in hormone binding. Endocrinology 135: 1488–1495, 1994.
Luck MD, Carter PH, Gardella TJ: The (1-14) fragment of parathyroid hormone (PTH) activates intact and amino-terminally truncated PTH-1 receptors. Mol Endocrinol 13: 670–680, 1999.
Costanzo LS, Windhager EE: Effects of PTH, ADH, and cyclic AMP on distal tubular Ca and Na reabsorption. Am J Physiol 239: F478–F485, 1980.
Agus ZS, Puschett JB, Senesky D, Goldberg M: Mode of action of parathyroid hormone and cyclic adenosine 3′,5′-monophosphate on renal tubular phosphate reabsorption in the dog. J Clin Invest 50: 617–626, 1971.
Bank N, Aynedjian HS, Weinstein SW: A microperfusion study of phosphate reabsorption by the rat proximal renal tubule. Effect of parathyroid hormone. J Clin Invest 54: 1040–1048, 1974.
Kremer R, Goltzman D: Parathyroid hormone stimulates mammalian renal 25-hydroxyvitamin D3-1 alpha-hydroxylase in vitro. Endocrinology 110: 294–296, 1982.
Nesbitt T, Drezner MK, Lobaugh B: Abnormal parathyroid hormone stimulation of 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the hypophosphatemic mouse. Evidence for a generalized defect of vitamin D metabolism. J Clin Invest 77: 181–187, 1986.
Wein MN, Kronenberg HM: Regulation of bone remodeling by parathyroid hormone. Cold Spring Harb Perspect Med 8: a031237, 2018.
Amizuka N, Goltzman D, Ozawa H: The biologic action of parathyroid hormone-related peptide on bone and cartilage cells. Tissue Eng 2: 277–287, 1996.
Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345–357, 1999.
Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P, et al.: Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol 4: 186–194, 2009.
Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, et al.: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370–1378, 2011.
Patel S, Barron JL, Mirzazedeh M, Gallagher H, Hyer S, Cantor T, et al.: Changes in bone mineral parameters, vitamin D metabolites, and PTH measurements with varying chronic kidney disease stages. J Bone Miner Metab 29: 71–79, 2011.
Kritmetapak K, Losbanos L, Berent TE, Ashrafzadeh-Kian SL, Algeciras-Schimnich A, Hines JM, et al.: Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH) 2 D and normal FGF7 concentrations characterize patients with CKD. BMC Nephrol 22: 114, 2021.
Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, Gao P, Cantor T, et al.: Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 147: 123–131, 2002.
Canney M, Djurdjev O, Tang M, Zierold C, Blocki F, Wolf M, et al.: GFR-specific versus GFR-agnostic cutoffs for parathyroid hormone and fibroblast growth factor-23 in advanced chronic kidney disease. Am J Nephrol 50: 105–114, 2019.
Yamashita H, Gao P, Cantor T, Futata T, Murakami T, Uchino S, et al.: Large carboxy-terminal parathyroid hormone (PTH) fragment with a relatively longer half-life than 1-84 PTH is secreted directly from the parathyroid gland in humans. Eur J Endocrinol 149: 301–306, 2003.
Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al.: A novel mechanism for skeletal resistance in uremia. Kidney Int 58: 753–761, 2000.
D’Amour P, Brossard JH, Rousseau L, Nguyen-Yamamoto L, Nassif E, Lazure C, et al.: Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 68: 998–1007, 2005.
Huan J, Olgaard K, Nielsen LB, Lewin E: Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol 17: 1923–1930, 2006.
Singh RJ, Hines JM, Lopez MF, Krastins B, Hoofnagle AN: Mass spectrometric immunoassay raises doubt for the existence of parathyroid hormone fragment 7-84. Clin Chem 61: 558–560, 2015.
Divieti P, Geller AI, Suliman G, Jüppner H, Bringhurst FR: Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: Determinants of ligand binding and bioactivity. Endocrinology 146: 1863–1870, 2005.
Hruska KA, Korkor A, Martin K, Slatopolsky E: Peripheral metabolism of intact parathyroid hormone. Role of liver and kidney and the effect of chronic renal failure. J Clin Invest 67: 885–892, 1981.
Hocher B, Armbruster FP, Stoeva S, Reichetzeder C, Grön HJ, Lieker I, et al.: Measuring parathyroid hormone (PTH) in patients with oxidative stress--do we need a fourth generation parathyroid hormone assay? PLoS One 7: e40242, 2012.
Hocher B, Oberthür D, Slowinski T, Querfeld U, Schaefer F, Doyon A, et al.: Modeling of oxidized PTH (oxPTH) and non-oxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients. Kidney Blood Press Res 37: 240–251, 2013.
Tepel M, Armbruster FP, Grön HJ, Scholze A, Reichetzeder C, Roth HJ, et al.: Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients. J Clin Endocrinol Metab 98: 4744–4751, 2013.
Seiler-Mussler S, Limbach AS, Emrich IE, Pickering JW, Roth HJ, Fliser D, et al.: Association of nonoxidized parathyroid hormone with cardiovascular and kidney disease outcomes in chronic kidney disease. Clin J Am Soc Nephrol 13: 569–576, 2018.
Ursem SR, Heijboer AC, D’Haese PC, Behets GJ, Cavalier E, Vervloet MG, et al.: Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease. Kidney Int 99: 1173–1178, 2021.
Arya AK, Sachdeva N: Parathyroid Hormone (PTH) Assays and Applications to Bone Disease: Overview on Methodology. In: Biomarkers in Bone Disease: Methods, Discoveries and Applications, edited by Preedy V, The Netherlands, Springer, 2015, pp 1–29.
Torres PU: The need for reliable serum parathyroid hormone measurements. Kidney Int 70: 240–243, 2006.
Cavalier E, Daly AF, Betea D, Pruteanu-Apetrii PN, Delanaye P, Stubbs P, et al.: The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 95: 3745–3749, 2010.
Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al.: Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70: 345–350, 2006.
Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barré M, D’Amour P: Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values. J Clin Endocrinol Metab 81: 3923–3929, 1996.
Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, et al.: Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 46: 697–703, 2000.
Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP, et al.: Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: Importance of the reference (normal) values. Nephrol Dial Transplant 27: 1950–1956, 2012.
Cavalier E, Vasikaran S, Bhattoa HP, Heijboer AC, Makris K, Ulmer CZ: The path to the standardization of PTH: Is this a realistic possibility? A position paper of the IFCC C-BM. Clin Chim Acta 515: 44–51, 2021.
Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al.: The spectrum of bone disease in end-stage renal failure--an evolving disorder. Kidney Int 43: 436–442, 1993.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 7: 1–59, 2011.
National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1–S201, 2003.
John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H: A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84: 4287–4290, 1999.
D’Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T: Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 49: 2037–2044, 2003.
D’Amour P, Brossard JH, Räkel A, Rousseau L, Albert C, Cantor T: Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 51: 169–176, 2005.
Gao P, Scheibel S, D’Amour P, John MR, Rao SD, Schmidt-Gayk H, et al.: Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16: 605–614, 2001.
Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, et al.: Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63: 1801–1808, 2003.
Lehmann G, Stein G, Hüller M, Schemer R, Ramakrishnan K, Goodman WG: Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 68: 1206–1214, 2005.
Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al.: Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67: 559–566, 2016.
Heaney LM: Advancements in mass spectrometry as a tool for clinical analysis: Part I. Clin Chem Lab Med 58: 639–642, 2020.
Kumar V, Barnidge DR, Chen LS, Twentyman JM, Cradic KW, Grebe SK, et al.: Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin Chem 56: 306–313, 2010.
Sage AP, Lu J, Atti E, Tetradis S, Ascenzi MG, Adams DJ, et al.: Hyperlipidemia induces resistance to PTH bone anabolism in mice via oxidized lipids. J Bone Miner Res 26: 1197–1206, 2011.
Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, et al.: Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 71: 738–743, 2007.
Alonso V, Magyar CE, Wang B, Bisello A, Friedman PA: Ubiquitination-deubiquitination balance dictates ligand-stimulated PTHR sorting. J Bone Miner Res 26: 2923–2934, 2011.
Drüeke TB: Is parathyroid hormone measurement useful for the diagnosis of renal bone disease? Kidney Int 73: 674–676, 2008.
Digby MG, Bishop NJ, Paggiosi MA, Offiah AC: HR-pQCT: a non-invasive ‘biopsy’ to assess bone structure and strength. Arch Dis Child Educ Pract Ed 101: 268–270, 2016.
معلومات مُعتمدة: P30 CA015083 United States CA NCI NIH HHS; R01 DK125252 United States DK NIDDK NIH HHS
فهرسة مساهمة: Keywords: mass spectrometry; mineral metabolism; parathyroid hormone
المشرفين على المادة: 0 (Parathyroid Hormone)
0 (Peptide Fragments)
تواريخ الأحداث: Date Created: 20220409 Date Completed: 20220802 Latest Revision: 20230802
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9342634
DOI: 10.1681/ASN.2022010036
PMID: 35396262
قاعدة البيانات: MEDLINE
الوصف
تدمد:1533-3450
DOI:10.1681/ASN.2022010036